INDV Q3 2025 Earnings — Indivior Pharmaceuticals Inc Revenue & Financial Results | Market Cap Arena

INDVIndivior Pharmaceuticals Inc

$4B

Q3 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$314M+2.3% YoY

Gross Profit

$230M73.2% margin

Operating Income

$43M13.7% margin

Net Income

$42M13.4% margin

EPS (Diluted)

$0.33

QoQ Revenue Growth

+4.0%

Cash Flow

Operating Cash Flow

-$39M

Free Cash Flow

-$59M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$1.6B

Stockholders' Equity

-$207M

Cash & Equivalents

$445M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$314M	$307M	+2.3%
Gross Profit	$230M	$238M	-3.4%
Operating Income	$43M	$4M	+975.0%
Net Income	$42M	$4M	+950.0%

Revenue Segments

Reportable Segment

$314M100%